The global Liquid Biopsy Market, valued at US$3.65 billion in 2024 stood at US$4.03 billion in 2025 and is projected to ...

PanTracer LBx will strengthen NeoGenomics’ pan-solid tumor CGP portfolio and position it in the growing $3 to $5 billion ...

UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company’s ...

Liquid biopsy technologies are maturing at a rapid pace. They are already being used as a precision medicine tool, helping clinicians match a patient’s cancer to targeted therapies.

Liquid biopsy’s potential as a diagnostic in cancer is gaining recognition, and its advantages over tissue biopsy in non-small cell lung cancer (NSCLC) were featured in research recently ...

Q2 2025 Management View Helmy Eltoukhy, Co-CEO, stated that "Q2 marked another exceptional quarter for Guardant. We continue to build momentum across oncology, biopharma and screening business lines, ...

LONDON--(BUSINESS WIRE)--The global liquid biopsy market is expected to grow by USD 4.02 billion as per Technavio. This marks a significant market slow down compared to the 2019 growth estimates ...

The two liquid biopsy panels compared were the Guardant360, from Guardant Health, Inc., which sequenced at least part of the coding sequences of 73 genes, and the PlasmaSELECT panel from Personal ...